Bone mineral content and mineral metabolism during cyclosporine treatment of nephrotic Syndrome

J Pediatr. 2006 Sep;149(3):383-9. doi: 10.1016/j.jpeds.2006.04.060.

Abstract

Objective: Although cyclosporine (Cy) has been associated with bone loss following transplantation, its effects on bone in growing children are largely unknown.

Study design: Thirty-seven patients (2-16 years of age) with remitting nephrotic syndrome (NS), n = 16 receiving Cy for 39 +/- 27 months and n = 21 without Cy, underwent mineral metabolism and bone turnover assessment. In 28 of 37 patients, bone mineral density (BMD) was obtained while off corticosteroid therapy (Rx).

Results: Urinary calcium (Ca), phosphate (PO(4)), and magnesium (Mg) excretion was normal, but serum Mg was lower in patients receiving Cy (1.8 +/- 0.1 v 1.95 +/- 0.2 mg/dL, P < .05). BMD Z scores were similar at the spine (-0.45 +/- 0.74 v 0.04 +/- 0.9) and femur (-0.17 +/- 0.52 v 0.38 +/- 1.28) with no Z score <-2. Serum bone-specific alkaline phosphatase was normal, and N-telopeptide of type I collagen also normal, was higher on Cy (P < .05). Cumulative prednisone exposure was similar and had no significant effect on height and BMD Z scores. Length of Cy-Rx and time elapsed from onset of NS did not correlate with BMD, height Z score, or markers of bone turnover.

Conclusions: In growing children with NS, during long-term Cy-Rx urinary wasting of Ca and Mg was absent and bone density was preserved.

MeSH terms

  • Adolescent
  • Bone Density / drug effects*
  • Bone Remodeling / drug effects*
  • Child
  • Child, Preschool
  • Cyclosporine / administration & dosage*
  • Drug Administration Schedule
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Minerals / metabolism*
  • Nephrotic Syndrome / drug therapy
  • Nephrotic Syndrome / metabolism*
  • Retrospective Studies

Substances

  • Immunosuppressive Agents
  • Minerals
  • Cyclosporine